Survival and Safety Outcomes of Avelumab Maintenance Therapy for Advanced Urothelial Carcinoma from a Single-Center Experience
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Avelumab maintenance therapy shows promising survival outcomes and good tolerability for advanced urothelial carcinoma (UC) in Japanese real-world practice. This treatment offers a viable option for patients with advanced UC post-chemotherapy.
Area Of Science
- Oncology
- Immunotherapy
- Urothelial Carcinoma Research
Background
- Avelumab maintenance therapy is effective for advanced urothelial carcinoma (UC) after first-line chemotherapy.
- Real-world data on avelumab's survival outcomes in Japan are limited.
Purpose Of The Study
- To evaluate the real-world clinical outcomes of avelumab maintenance therapy in advanced UC patients in Japan.
- To assess the efficacy, survival, and safety of avelumab in a Japanese patient cohort.
Main Methods
- Retrospective study of 22 advanced UC patients receiving avelumab maintenance therapy.
- Analysis of clinical outcomes, including efficacy, survival (PFS, OS), and safety (irAEs).
Main Results
- Objective response rate was 4.5%, disease control rate was 50.0%.
- Median progression-free survival (PFS) was 3.3 months; median overall survival was 22.2 months.
- No grade ≥3 immune-related adverse events (irAEs) were observed; PFS was longer for patients with prior complete/partial response to chemotherapy.
Conclusions
- Avelumab maintenance therapy demonstrates favorable survival outcomes in advanced UC patients in a real-world Japanese setting.
- The therapy is well-tolerated, with a manageable safety profile.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...